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ABSTRACT
Objective Spirometric Z scores by lambda-mu-sigma
(LMS) rigorously account for age-related changes in lung
function. Recently, the Global Lung Function Initiative
(GLI) expanded LMS spirometric Z scores to multiple
ethnicities. Hence, in aging populations, the GLI provides
an opportunity to rigorously evaluate ethnic differences
in respiratory impairment, including airflow limitation
and restrictive pattern.
Methods Using data from the Third National Health
and Nutrition Examination Survey, including participants
aged 40–80, we evaluated ethnic differences in
GLI-defined respiratory impairment, including prevalence
and associations with mortality and respiratory
symptoms.
Results Among 3506 white Americans, 1860 African
Americans and 1749 Mexican Americans, the prevalence
of airflow limitation was 15.1% (13.9% to 16.4%),
12.4% (10.7% to 14.0%) and 8.2% (6.7% to 9.8%),
and restrictive pattern was 5.6% (4.6% to 6.5%), 8.0%
(6.9% to 9.0%) and 5.7% (4.5% to 6.9%), respectively.
Airflow limitation was associated with mortality in white
Americans, African Americans and Mexican Americans—
adjusted HR (aHR) 1.66 (1.23 to 2.25), 1.60 (1.09 to
2.36) and 1.80 (1.17 to 2.76), respectively, but
associated with respiratory symptoms only in white
Americans—adjusted OR (aOR) 2.15 (1.70 to 2.73).
Restrictive pattern was associated with mortality but only
in white Americans and African Americans—aHR 2.56
(1.84 to 3.55) and 3.23 (2.06 to 5.05), and associated
with respiratory symptoms but only in white Americans
and Mexican Americans—aOR 2.16 (1.51 to 3.07) and
2.12 (1.45 to 3.08), respectively.
Conclusions In an aging population, we found ethnic
differences in GLI-defined respiratory impairment. In
particular, African Americans had high rates of
respiratory impairment that were associated with
mortality but not respiratory symptoms.
INTRODUCTION
Prior work suggests that ethnic differences exist in
respiratory disease.1–3 For example, as reported by
the Centers for Disease Control and Prevention
(USA), prevalence rates for chronic bronchitis and
emphysema are higher in white Americans than in
African Americans or Hispanics.1 2 Similarly,
age-adjusted death rates for chronic obstructive pul-
monary disease (COPD), defined as chronic bron-
chitis or emphysema, are higher in white Americans
than in African Americans or Hispanics.1 3 These epi-
demiologic data have limitations, however, for at
least two reasons.1–7 First, confirmation of airway
obstruction as a criterion for diagnosing COPD is
underutilised in clinical practice—that is, chronic
bronchitis and emphysema may occur in the absence
of airway obstruction and vice versa.4 5 7 Second,
death certificates in patients with respiratory disease
may misclassify the cause of death.6
Spirometry provides an objective evaluation of
respiratory disease, including potential ethnic differ-
ences.8 9 In particular, respiratory disease is often
established by a reduction in spirometric function,
heretofore termed a respiratory impairment, and is
subsequently categorised as airflow limitation (airway
obstruction) or restrictive pattern.3 9 10 Importantly,
because respiratory disease occurs more frequently in
aging populations (≥40 years),1 2 the spirometric cri-
teria that establish respiratory impairment must
account for age-related reductions in lung function
and the age-related variability in spirometric per-
formance.9–18
The lambda-mu-sigma (LMS) method rigorously
accounts for age-related changes in lung function by
using Z-scores that incorporate the mean (mu)—
representing how spirometric measures change based
on predictor variables (age and height); the coeffi-
cient of variation (sigma)—representing the spread of
reference values; and skewness (lambda)—
Key messages
What is the key question?
▸ In aging populations, are there ethnic
differences in respiratory impairment?
What is the bottom line?
▸ Lambda-mu-sigma (LMS)-calculated spirometric
Z scores rigorously account for age-related
changes in lung function. Recently, the Global
Lung Function Initiative (GLI) expanded the
availability of LMS spirometric Z scores to
multiple ethnicities. Hence, in aging
populations, the GLI provides an opportunity to
rigorously evaluate ethnic differences in
respiratory impairment, including spirometric
airflow limitation and restrictive pattern.
Why read on?
▸ In a large sample of people aged 40–80, we
found ethnic differences in GLI-defined
respiratory impairment, including prevalence
rates and associations with health outcomes. In
particular, African Americans present a unique
public health challenge, with high rates of
respiratory impairment being associated with
increased mortality but not respiratory
symptoms.
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representing departure from normality.11 12 A Z score of −1.64
defines the lower limit of normal (LLN) as the fifth percentile of
the distribution.11 12 Notably, using data from large reference
populations of asymptomatic lifelong non-smokers, the Global
Lung Function Initiative (GLI) has recently published equations
that expand the availability of LMS-calculated spirometric Z
scores, allowing respiratory impairment to be established across
multiple ethnicities (see Methods).12
Whether ethnic differences exist in GLI-defined respiratory
impairment has not yet been evaluated. Therefore, using
GLI-based spirometric criteria and data from the Third National
Health and Nutrition Examination Survey (NHANES III)19—
including participants aged 40–80 who were specifically identified
as white Americans, African Americans and Mexican Americans—
we calculated prevalence rates for airflow limitation and restrictive
pattern, and their corresponding associations with 5-year all-cause
mortality and respiratory symptoms. As a secondary aim, we also
evaluated sex and smoking history as potential effect modifiers of
the associations of interest. The results of the present study may
inform public health policy and clinical practice regarding ethnic
differences in respiratory impairment.
METHODS
Study population
NHANES III is a national probability sample of Americans aged
8–80, assembled in 1988–1994, with white Americans, African
Americans and Mexican Americans representing the three
largest ethnic groups. A separate Hispanic category was also
identified but comprised only 2.4% of the NHANES III
cohort.19 Given our specific aims, our analytical sample there-
fore included participants aged 40–80 who were white
Americans, African Americans or Mexican Americans and who,
at baseline, had no self-reported asthma and had completed at
least two American Thoracic Society (ATS) acceptable spiro-
metric manoeuvres (the maximal exhalation manoeuvre contin-
ued for at least 6 s, with a minimum 2 s terminal plateau).19 We
selected age ≥40 because respiratory impairment and its related
mortality are unusual in younger people.1 3 We excluded partici-
pants who had self-reported asthma to focus on COPD as the
cause of airflow limitation (see online supplementary appendix
table A1, regarding frequency distributions of self-reported
asthma, stratified by ethnicity and spirometric categories).
The institutional review boards from the Veterans Affairs
Connecticut Healthcare System and Yale University approved
the study, granting exemption from participant consent because
it involved de-identified data that were publicly available.
Clinical measures
NHANES III recorded all-cause mortality, ascertained from a
public use linked mortality file that contained information based
on the National Death Index.20 For the present study, mortality
surveillance occurred over 5 years.
NHANES III also recorded respiratory symptoms at the base-
line visit, including chronic bronchitis, wheezing and dyspnoea.
Specifically, participants were classified as having respiratory
symptoms if they answered ‘yes’ to any of the following four
questions19: ‘Do you usually cough on most days for three con-
secutive months or more during the year?’; ‘Do you bring up
phlegm on most days for three consecutive months or more
during the year?’; ‘Have you had wheezing or whistling in your
chest at any time in the past 12 months?’; or ‘Are you troubled
by shortness of breath when hurrying on level ground or
walking up a slight hill?’.
Other clinical data included age, sex, height, body mass index
(BMI), ethnicity, health status, chronic conditions and smoking
history.21 Reduced health status was defined as a self-reported
rating of ‘fair-to-poor’. Chronic conditions included self-
reported, physician-diagnosed hypertension, COPD, diabetes,
stroke, myocardial infarction and heart failure. For a smoking
history to be established, ≥10 pack-years of cigarette consump-
tion was required. Participants were also classified as having
high cardiovascular (CV) risk based on BMI ≥30 or having a
history of hypertension, diabetes, stroke, myocardial infarction
or heart failure.
Spirometry
At the baseline visit, spirometry was performed using ATS pro-
tocols.19 21 The measures of interest included the forced vital
capacity (FVC) and forced expiratory volume in 1 s (FEV1).
Using the largest set of FEV1 and FVC values that were
recorded in any of the ATS-acceptable spirometric manoeuvres,
the FEV1/FVC was also calculated.
8 9 19 21 These spirometric
measures were then expressed as Z scores, using the GLI
equations.12
As per recommendations from the ATS and European
Respiratory Society, the diagnostic threshold for spirometric
measures was set at the fifth percentile of distribution, defining
the LLN.9 In addition, because a substantial proportion of parti-
cipants had risk factors for respiratory impairment, including
smoking history, respiratory symptoms, and high cardiovascular
risk, the LLN at the 5th percentile was also deemed more clinic-
ally appropriate than the 2.5th percentile, which is otherwise
recommended for screening only.9 11 12 In the present study, the
LLN was thus defined by a Z score of −1.64, corresponding to
the fifth percentile of the distribution of Z scores.10–18 The
respiratory status of each participant was then categorised as
normal spirometry (FEV1/FVC and FVC, both ≥LLN) or
respiratory impairment, including airflow limitation (FEV1/FVC
<LLN) or restrictive pattern (FEV1/FVC≥LLN but FVC<LLN).
Statistical analysis
Baseline characteristics and the frequency distributions of
respiratory impairment, respiratory symptoms and death were
first summarised as means and SEs, or as counts and percen-
tages. Ethnic differences were compared using the Rao–Scott χ2
test for categorical variables and least squares regression for con-
tinuous variables. p Values were adjusted for multiple compari-
sons using the false discovery rate procedure.22
The association between respiratory impairment and death
was then evaluated using Cox regression models. The following
covariates, identified a priori as clinically plausible confounders,
were entered into the adjusted model (regardless of their level
of statistical significance): age, sex, smoking history, high CV
risk and reduced health status. Airflow limitation and restrictive
pattern were treated as nominal categories, with the reference
group including participants who had normal spirometry. Each
model’s goodness of fit was assessed by model-fitting procedures
and by the analysis of residuals. The proportional hazards
assumption was tested by using interaction terms for the
time-to-event outcome and each variable in the multivariable
model; the terms were retained if p<0.05 after adjusting for the
multiplicity of comparisons. Higher-order effects were tested
for the continuous covariates and included in the final model if
they met a forward selection criterion of p<0.20.
Similarly, the association between respiratory impairment and
respiratory symptoms at baseline was evaluated by calculating
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ORs, using logistic regression models. Covariates in the adjusted
model were as described previously.
Lastly, potential effect modifiers of associations with health
outcomes were assessed. In these analyses, interactions for each
ethnic group were evaluated and involved ‘crossing’ sex and
smoking history, with airflow limitation and restrictive pattern.
HRs for death and ORs for respiratory symptoms were esti-
mated according to sex and smoking history, using separate
regression models for each ethnic group and combinations of
effect modifiers. In tests of potential effect modification, p
values for interaction terms were not adjusted for the multipli-
city of comparisons, because the clinical interest was toward
avoiding type II errors, rather than type I errors. Covariates
included age, sex, smoking history, high CV risk and reduced
health status, without the variable that was the effect modifier
of interest.
SAS V.9.3 software (SAS Institute Inc 2011; Cary, North
Carolina, USA) was used in the analyses, with a p<0.05 (two
sided) denoting statistical significance. The analyses accounted
for the complex study design to obtain accurate SEs, but did not
use sampling weights because post hoc deletions were made to
the national NHANES III probability sample.
RESULTS
Table 1 summarises baseline characteristics according to ethni-
city. Significant differences were as follows: white Americans
were older and had the highest rates of having a smoking
history and (self-reported, physician-diagnosed) COPD or myo-
cardial infarction, but the lowest rates of obesity (BMI≥30) and
reduced health status. African Americans had the highest rate of
CV risk, including hypertension. Mexican Americans had the
highest rates of diabetes and reduced health status, but the
lowest rates of having a smoking history, hypertension or stroke.
Table 2 summarises respiratory impairment, respiratory symp-
toms and mortality according to ethnicity. Overall, the preva-
lence of airflow limitation varied in a progression of white
Table 1 Baseline characteristics according to ethnicity
Characteristic
White Americans
N=3506
African Americans
N=1860
Mexican Americans
N=1749
Adjusted p value
W vs A W vs M A vs M
Age (years), mean (SE) 60.7 (0.4) 56.0 (0.5) 56.0 (0.4) <0.001 <0.001 0.923
Women, n (%) 1830 (52.2) 968 (52.0) 847 (48.4) 0.923 0.101 0.066
BMI (kg/m2), mean (SE) 27.2 (0.1) 28.5 (0.2) 28.6 (0.2) <0.001 < 0.001 0.905
BMI≥30, n (%) 878 (25.0) 636 (34.2) 589 (33.9) <0.001 < 0.001 0.905
Smoking history, n (%)
<10 pack-years 1950 (56.1) 1183 (64.9) 1265 (73.2) <0.001 <0.001 <0.001
≥10 pack-years 1524 (43.9) 641 (35.1) 462 (26.8)
Chronic conditions, n (%)*
Hypertension 1279 (36.5) 859 (46.3) 530 (30.5) <0.001 0.003 <0.001
COPD† 319 (9.1) 93 (5.0) 66 (3.8) <0.001 <0.001 0.139
Diabetes mellitus 299 (8.5) 246 (13.2) 312 (17.8) <0.001 <0.001 <0.001
Myocardial infarction 265 (7.6) 96 (5.2) 79 (4.7) 0.002 0.001 0.506
Stroke 134 (3.8) 80 (4.3) 44 (2.5) 0.430 0.014 0.004
Heart failure 127 (3.6) 89 (4.8) 105 (6.0) 0.065 <0.001 0.165
High CV risk, n (%)‡ 1885 (53.8) 1233 (66.3) 1021 (58.4) <0.001 0.020 < 0.001
Reduced health status, n (%) 672 (19.2) 609 (32.8) 731 (41.8) <0.001 <0.001 <0.001
*Self-reported, physician diagnosed.
†Included chronic bronchitis or emphysema.
‡Included the presence of any of the following: BMI>30, hypertension, diabetes, heart failure, stroke or myocardial infarction.
A, African Americans; BMI, body mass index (weight in kg divided by height in m2); COPD, chronic obstructive pulmonary disease; CV, cardiovascular; M, Mexican Americans; W, white
Americans.
Table 2 Spirometry and health outcomes according to ethnicity
Characteristic
White Americans N=3506 African Americans N=1860
Mexican Americans
N=1749 Adjusted p value
n % (95% CI) n % (95% CI) n % (95% CI) W vs A W vs M A vs M
Spirometry*
Normal 2778 79.3 (77.8 to 80.7) 1482 79.7 (77.7 to 81.7) 1504 86.0 (84.3 to 87.8) 0.780 <0.001 <0.001
Airflow limitation 531 15.1 (13.9 to 16.4) 230 12.4 (10.7 to 14.0) 144 8.2 (6.7 to 9.8) 0.014 <0.001 0.002
Restrictive pattern 196 5.6 (4.6 to 6.5) 148 8.0 (6.9 to 9.0) 100 5.7 (4.5 to 6.9) 0.002 0.863 0.016
Health outcomes
Respiratory symptoms† 1452 41.5 (39.2 to 43.8) 668 36.0 (33.5 to 38.5) 604 34.6 (31.9 to 37.3) <0.001 <0.001 0.541
Deaths, n (%)‡ 308 8.8 (7.6 to 10.0) 173 9.3 (8.0 to 10.6) 121 6.9 (5.4 to 8.4) 0.632 0.063 0.039
*Recorded at baseline: normal spirometry was defined by FEV1/FVC and FVC, both >LLN; airflow limitation by FEV1/FVC<LLN; and restrictive pattern by FEV1/FVC>LLN and FVC<LLN.
Missing data: white Americans (n=1); Mexican Americans (n=1).
†Recorded at baseline: chronic cough or sputum production, dyspnoea on exertion, or wheezing. Missing data: white Americans (n=6); Mexican Americans (n=3); African Americans
(n=4).
‡Over 5 years of follow-up. Vital status was missing for three white Americans and two Mexican Americans.
A, African Americans; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LLN, lower limit of normal; M, Mexican Americans; W, white Americans.
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Americans>African Americans>Mexican Americans, whereas
restrictive pattern varied in a progression of African
Americans>Mexican Americans and White Americans. Whereas
airflow limitation exceeded the 5% prevalence level that is
expected for a normal population (using our LLN threshold)
across the three ethnicities, restrictive pattern exceeded the 5%
prevalence level only in African Americans. The frequency of
respiratory symptoms varied in a progression of White
Americans>African Americans and Mexican Americans. The
frequency of deaths over 5 years varied in a progression of
African Americans and White Americans>Mexican Americans.
Table 3 shows adjusted HRs (aHRs) for death, according to
spirometric category and ethnicity. Relative to normal spirom-
etry, airflow limitation was associated with mortality in white
Americans, African Americans and Mexican Americans—aHR
1.66 (1.23 to 2.25), 1.60 (1.09 to 2.36) and 1.80 (1.17 to
2.76), respectively. Restrictive pattern was associated with mor-
tality in white Americans and African Americans—aHR 2.56
(1.84 to 3.55) and 3.23 (2.06 to 5.05), respectively. Mexican
Americans also had an increased aHR but this was not statistic-
ally significant—aHR 2.09 (0.89 to 4.90). In these analyses of
mortality, there were no significant interactions between respira-
tory impairment and ethnicity (ie, HRs were similar).
Table 4 shows adjusted ORs (aORs) for respiratory symptoms,
according to spirometric category and ethnicity. Relative to
normal spirometry, airflow limitation was associated with
respiratory symptoms in white Americans, but had only border-
line statistical significance in African Americans and was not
associated in Mexican Americans—aOR 2.15 (1.70 to 2.73),
1.38 (0.99 to 1.92) and 1.26 (0.90 to 1.76), respectively.
Restrictive pattern was associated with respiratory symptoms in
white Americans and Mexican Americans but not African
Americans—aOR 2.16 (1.51 to 3.07), 2.12 (1.45 to 3.08) and
1.08 (0.70 to 1.67), respectively. In these analyses of respiratory
symptoms, there were significant interactions between respira-
tory impairment and ethnicity, with African Americans in par-
ticular having weak to no associations (ie, ORs were
significantly lower, relative to white Americans).
Effect modification by sex and smoking history of the associ-
ation between respiratory impairment and mortality were not
significant (data not shown). In contrast, and as shown in
figures 1 and 2, the aOR for respiratory symptoms was signifi-
cantly modified in several situations: sex, among African
Americans who had airflow limitation—aOR 0.86 (0.55 to
1.34) and 1.93 (1.18 to 3.17) for women and men, respectively
(p=0.010), and among African Americans who had restrictive
pattern—aOR 0.83 (0.53 to 1.31) and 1.66 (0.90 to 3.07) for
women and men, respectively (p=0.024); and (2) smoking
history, among white Americans who had airflow limitation—
aOR 1.48 (0.96 to 2.30) and 2.57 (1.94 to 3.41) for < and
≥10 pack-years, respectively (p=0.025).
DISCUSSION
In a large sample of people aged 40–80, we found that
GLI-defined respiratory impairment differed in the following:
prevalence: airflow limitation was more common in white
Americans and African Americans than Mexican Americans,
while restrictive pattern was more common in African
Table 3 HRs for 5-year mortality, according to spirometric category and stratified by ethnicity*
Spirometric category†
White Americans
N=3467
African Americans
N=1821
Mexican Americans
N=1717
HRs for 5-year mortality (95% CI)‡§
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Normal 1.00
Airflow limitation 2.31 (1.75 to 3.06) 1.66 (1.23 to 2.25) 2.58 (1.91 to 3.50) 1.60 (1.09 to 2.36) 2.18 (1.39 to 3.40) 1.80 (1.17 to 2.76)
Restrictive pattern 3.10 (2.30 to 4.17) 2.56 (1.84 to 3.55) 2.91 (1.88 to 4.50) 3.23 (2.06 to 5.05) 2.88 (1.34 to 6.21) 2.09 (0.89 to 4.90)
*Missing data: white Americans—37 missing covariates, 2 missing mortality; African Americans—39 missing covariates; and Mexican Americans—30 missing covariates, 2 missing
mortality.
†See footnote to table 2 for description of spirometric category.
‡Values were calculated using three separate Cox regression models for each of the ethnic groups. In the adjusted models, covariates included age, sex, smoking history, high
cardiovascular risk and health status. In white Americans there was an age by time interaction added to the model, while in African Americans age2, and age3 were also included.
§Relative to white Americans, there were no significant interactions in African American×airflow limitation (p=0.673), African American×restrictive pattern (p=0.973), Mexican
American×airflow limitation (p=0.253) and Mexican American×restrictive pattern (p=0.189). These results suggest that the adjusted HRs did not differ significantly by ethnicity.
Table 4 ORs for respiratory symptoms, according to spirometric category and stratified by ethnicity*
Spirometric category†
White Americans
N=3465
African Americans
N=1821
Mexican Americans
N=1716
ORs for respiratory symptoms (95% CI)‡§
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Normal 1.00
Airflow limitation 2.70 (2.20 to 3.32) 2.15 (1.70 to 2.73) 1.41 (1.02 to 1.94) 1.38 (0.99 to 1.92)§ 1.25 (0.90 to 1.72) 1.26 (0.90 to 1.76)§
Restrictive pattern 2.67 (1.90 to 3.76) 2.16 (1.51 to 3.07) 1.41 (0.96 to 2.08) 1.08 (0.70 to 1.67)§ 2.60 (1.92 to 3.52) 2.12 (1.45 to 3.08)
*Missing data: white Americans—37 missing covariates and 4 missing respiratory symptoms; African Americans—39 missing covariates, 4 missing respiratory symptoms; Mexican
Americans—30 missing covariates, 3 missing respiratory symptoms.
†See footnote to table 2 for description of spirometric category.
‡ORs were calculated using three separate logistic regression models for each ethnic group. In the adjusted models, covariates included age, sex, smoking history, high cardiovascular
risk and health status.
§Relative to white Americans, there were significant interactions in African American×airflow limitation (p=0.003), African American×restrictive pattern (p=0.012) and Mexican
American×airflow limitation (p=0.001), but no significant interaction in Mexican American×restrictive pattern (p=0.669).
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Americans than white Americans or Mexican Americans; (2) all-
cause mortality: airflow limitation was associated with mortality
in all three ethnic groups, while restrictive pattern was asso-
ciated with mortality only in white Americans and African
Americans—furthermore, the magnitude of these associations
did not differ by ethnicity; respiratory symptoms: airflow limita-
tion was associated with respiratory symptoms but only in white
Americans, while restrictive pattern was associated with respira-
tory symptoms but only in white Americans and Mexican
Americans—furthermore, the magnitude of these associations
Figure 1 Adjusted OR (95% CI) for respiratory symptoms among participants who had airflow limitation, stratified by effect modifier—sex (A) and
smoking history (B). Separate logistic regression models were used for each ethnic group and effect modifier combination, with normal spirometry as
the reference group. Covariates included age, sex, smoking history, high CV risk and reduced health status, without the variable that was the effect
modifier of interest. (A) Airflow limitation×sex (significant interaction in African Americans, p=0.010). (B) Airflow limitation×smoking history
(significant interaction in white Americans, p=0.025). CV, cardiovascular.
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differed by ethnicity, with African Americans in particular
having weak to no associations; and effect modification: female
sex decreased the association of airflow limitation and restrictive
pattern with respiratory symptoms but only in African
Americans, while smoking history increased the association of
airflow limitation with respiratory symptoms but only in white
Figure 2 Adjusted OR (95% CI) for respiratory symptoms among participants who had restrictive pattern, stratified by effect modifier—sex (A) and
smoking history (B). Separate logistic regression models were used for each ethnic group and effect modifier combination, with normal spirometry as
the reference group. Covariates included age, sex, smoking history, high CV risk, and reduced health status, without the variable that was the effect
modifier of interest. (A) Restrictive pattern×sex (significant interaction in African Americans, p=0.024). (B) Restrictive pattern×smoking history (no
significant interaction). CV, cardiovascular.
60 Vaz Fragoso CA, et al. Thorax 2014;69:55–62. doi:10.1136/thoraxjnl-2013-203631
Respiratory epidemiology
group.bmj.com on March 2, 2016 - Published by http://thorax.bmj.com/Downloaded from 
Americans—otherwise, there was no effect modification for the
mortality outcome.
These results indicate that ethnic differences exist in
GLI-defined respiratory impairment, including prevalence rates,
associations with health outcomes, and effect modification. In
particular, African Americans present a unique public health
challenge, with high rates of respiratory impairment being asso-
ciated with mortality but not respiratory symptoms.
Our approach for evaluating ethnic differences in respiratory
impairment has a strong mathematical and clinical rationale. As
discussed earlier, GLI-defined respiratory impairment is based
on LMS-calculated spirometric Z scores that rigorously account
for age-related changes in lung function, including variability in
spirometric performance and skewness of reference data.11 12
As additional evidence supporting this approach in clinical prac-
tice, Z scores are routinely used to diagnose osteoporosis (bone
mineral density) and the LMS method is widely applied to con-
struct growth charts.11 23 In the current context, ethnic differ-
ences were also evaluated based on associations between
respiratory impairment and health outcomes. All-cause mortality
is a definitive outcome that is resistant to miscoding and has
been the primary endpoint in clinical trials.24 Respiratory symp-
toms, including dyspnoea, chronic bronchitis and wheezing, are
often the bases for pursuing healthcare.24–26
Because we excluded participants who had self-reported
asthma, the spirometric diagnosis of airflow limitation in the
present study was likely due to airway obstruction from COPD.
Hence, our results suggest that white Americans and African
Americans have significantly higher rates of spirometry-
confirmed COPD than Mexican Americans (table 2). These
higher rates may be due to a greater smoking exposure in white
Americans and African Americans, along with a possible ethnic-
specific protection in Mexican Americans.27
Because a reduced FVC is associated with the metabolic syn-
drome, coronary heart disease and sudden cardiac death,28–30
and because a reduced FVC is a required criterion for establish-
ing restrictive pattern,9 we postulate that a CV mechanism may
have been an important contributor to restrictive pattern in our
study population, including its association with health out-
comes.14 15 17 18 This is especially relevant to African
Americans. The latter group had the highest rates of CV risk
and restrictive pattern, whereas white Americans and Mexican
Americans had lower rates of CV risk and restrictive pattern
(tables 1 and 2, respectively).
The present study also demonstrated a differential impact of
ethnicity on associations with death and respiratory symptoms
(tables 3 and 4, respectively). For example, in adjusted analyses,
we found that white Americans who had airflow limitation or
restrictive pattern had a significant increase in the risk of death
and odds of having respiratory symptoms. In contrast, African
Americans who had restrictive pattern had a significant increase
in the risk of death but not in the odds of having respiratory
symptoms. Similarly, Mexican Americans who had airflow limi-
tation had a significant increase in the risk of death but not in
the odds of having respiratory symptoms. Lastly, ethnic differ-
ences on associations with respiratory symptoms, but not
death, were also seen regarding effect modification by female
sex, being significant only in African Americans, and by
smoking history, being significant only in white Americans
(figures 1 and 2).
The differential impact of ethnicity on associations with
respiratory symptoms may affect prevalence rates for respiratory
disease. In particular, we found that the rate of airflow limitation
(spirometry-confirmed COPD) relative to self-reported, physician-
diagnosed COPD was higher in white Americans (15.1% vs
9.1%, respectively), yet more than doubled in African Americans
(12.4% vs 5.0%, respectively) and Mexican Americans (8.2% vs
3.8%, respectively) (tables 1 and 2). We postulate that the lower
rates of self-reported, physician-diagnosed COPD occurred
because spirometry is not routinely applied in clinical practice, or
participants may not have sought medical care, and because
respiratory symptoms are neither sufficient nor necessary to
establish clinically meaningful respiratory disease.5 7 16 Prior
work by our own group has shown, for example, that 31% of
participants who had moderate-to-severe spirometry-confirmed
COPD (based on FEV1 Z scores) had no respiratory symptoms.
16
In addition, the designation of self-reported, physician-diagnosed
COPD may have limited diagnostic accuracy. In the present study,
more than half of the participants who had self-reported,
physician-diagnosed COPD had normal spirometry (see online
supplementary appendix table A2).
In light of the above discussion, future work should evaluate
additional health outcomes, including other verbal descriptors
of dyspnoea, measures of health-related quality of life, and exer-
cise capacity (6 min walk test), across multiple ethnicities.31 32
Moreover, because preventive healthcare is available (smoking
cessation, vaccinations, CV risk modification, and reduction of
indoor and outdoor air pollutants), health outcomes should also
be evaluated in people aged ≥40 who at baseline have a spiro-
metric respiratory impairment but no respiratory symptoms (as
defined in the present study).31 32 The latter assessment has pre-
cedence, given that the Framingham Risk Score is currently
recommended in all asymptomatic people aged ≥40, including
those without a clinical history of coronary heart disease.33
Although the present study used rigorous spirometric criteria,
at least three potential limitations are noted. First, NHANES III
does not provide sufficient data to confirm the pathophysiology
of respiratory impairment. For example, in addition to COPD,
airflow limitation could be due to asthma, given that spirometry
in NHANES III was not specifically obtained after a broncho-
dilator, that self-reported asthma (a key exclusion criterion) may
have been underreported by participants, and that longstanding
asthma may lead to irreversible airflow limitation.34 Similarly,
restrictive pattern as a basis for establishing pulmonary restric-
tion requires confirmation by a reduced total lung capacity, and
may have included several non-CV aetiologies.9 10 Second, self-
reported ethnicity may not be entirely accurate, potentially
leading to misclassification in the ethnic-specific reference equa-
tions that were used to calculate spirometric Z scores.12
Moreover, because pulmonary function like many clinical phe-
nomena occurs along a continuum, spirometric Z scores that are
just above or below the LLN may have limited diagnostic accur-
acy when evaluating a respiratory impairment. A potential
related limitation is that establishing the LLN at the 5th percent-
ile, rather than the 2.5th percentile (see methods),9 11 12 may
increase false-positive designations for respiratory impairment.
Nonetheless, the 2.5th percentile threshold may substantially
increase false-negative designations, particularly given that
NHANES III participants aged 40-80 frequently had a smoking
history, respiratory symptoms and high cardiovascular risk.
Third, there may be differences in cultural, geographical and
socioeconomic factors between and within the three ethnic cat-
egories.35 In particular, differences in sedentary behaviour could
alter the association between respiratory impairment and symp-
toms (exertional dyspnoea). To address these limitations, future
studies should include comprehensive tests of cardiopulmonary
function and an assessment of genetic, cultural, geographical
and socioeconomic factors.
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CONCLUSION
In a large sample of people aged 40–80, we found that signifi-
cant ethnic differences existed in GLI-defined respiratory
impairment, including prevalence rates, associations with health
outcomes and the presence of effect modifiers. In particular,
African Americans present a unique public health challenge,
with high rates of airflow limitation and restrictive pattern being
associated with increased mortality but not respiratory symp-
toms. These results may inform future research and public
health policy regarding ethnic differences in respiratory
impairment.
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